Search
Search Results
-
Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation
PurposeOur goal was to identify new anticancer agents approved by the US Food and Drug Administration (FDA) and the European Medical Agency (EMA)...
-
2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential
PurposeReview the literature to update the MASCC guidelines from 2016 for controlling nausea and vomiting with systemic cancer treatment of low and...
-
The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study
BackgroundTrifluridine/tipiracil (TAS-102) is an oral anticancer drug with adequate efficacy in unresectable colorectal cancer, but frequently also...
-
Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)—a systematic review and individual patient data meta-analysis
IntroductionAlthough there have been reports of chemotherapy-induced nausea and vomiting (CINV) beyond 120 h, its overall prevalence has not been...
-
Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review
PurposeThis study describes chemotherapy-induced nausea and vomiting (CINV) control rates in pediatric and adult patients who did or did not receive...
-
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021)
Among the side effects of anticancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most feared given its high prevalence,...
-
Evaluation of chemotherapy-induced nausea and vomiting in pediatric patients with high-grade glioma treated with lomustine—a case series
PurposeAlthough lomustine has been used as a chemotherapeutic agent for decades, no recommendation on appropriate chemotherapy-induced nausea and...
-
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis
BackgroundThe Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis 2023 was extensively revised to reflect the latest...
-
Prophylaxe von Übelkeit und Erbrechen nach medikamentöser Tumortherapie
The frequency and severity of nausea and/or vomiting in patients receiving anticancer drugs are influenced by numerous factors, e.g., by the specific...
-
Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting
BackgroundA personalized risk model (PRM) that can categorize patients into high or low risk of ≥ grade 2 acute and/or delayed chemotherapy-induced...
-
Palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting in pediatric patients: a meta-analysis
PurposeChemotherapy-induced nausea and vomiting (CINV) are common adverse events in patients undergoing emetogenic chemotherapy. Palonosetron, a...
-
Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis
PurposeTo identify effective and safe interventions to prevent acute phase chemotherapy-induced nausea and vomiting (CINV) in adult and pediatric...
-
Creation of a chemotherapy-induced nausea/vomiting dashboard to improve outcomes for pediatric cancer patients
PurposeTwo of the most common acute side effects of chemotherapy are nausea and vomiting. Nausea and vomiting impact quality of life, nutritional...
-
Anxiety in oncology outpatients is associated with perturbations in pathways identified in anxiety focused network pharmacology research
PurposeEvaluate for perturbed signaling pathways associated with subgroups of patients with low versus high levels of state anxiety. These pathways...
-
A retrospective study on chemotherapy-induced nausea and vomiting in highly/moderately emetogenic chemotherapy: incidence and prescribing practice
BackgroundChemotherapy-induced nausea vomiting (CINV) is a common and significant problem in oncology patients and rated as one of cancer...
-
Impact of worst pain severity and morning fatigue profiles on oncology outpatients’ symptom burden and quality of life
PurposePain and fatigue are common symptoms in oncology patients. In a sample of oncology outpatients receiving chemotherapy ( n = 1342), the study...
-
Comparison of the incidence of nausea and vomiting between linezolid and vancomycin using claims database: a retrospective cohort study
BackgroundNausea and vomiting during linezolid therapy have been reported as part of safety analyses in clinical trials. We have previously examined...
-
Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults
PurposePrescribing guideline-recommended anti-emetics is an effective strategy to prevent CINV. However, the rate of guideline-concordant care is not...
-
FLOT (a chemotherapy regimen for gastric/esophagogastric junction cancer): to be treated as a highly emetogenic regimen or a moderately emetogenic one? Comparison of the emetogenic potential of FLOT versus FOLFOX and TAC regimens
PurposeThe current study aimed at investigating the efficacy of aprepitant-containing triple antiemetic regimen in FLOT...
-
2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies...